AU3351593A - Difluoromethylenandrostenone derivatives and process for their preparation - Google Patents

Difluoromethylenandrostenone derivatives and process for their preparation

Info

Publication number
AU3351593A
AU3351593A AU33515/93A AU3351593A AU3351593A AU 3351593 A AU3351593 A AU 3351593A AU 33515/93 A AU33515/93 A AU 33515/93A AU 3351593 A AU3351593 A AU 3351593A AU 3351593 A AU3351593 A AU 3351593A
Authority
AU
Australia
Prior art keywords
formula
compound
symbol
group
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU33515/93A
Inventor
Franco Buzzetti
Angelo Crugnola
Enrico Di Salle
Antonio Longo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Farmitalia Carlo Erba SRL
Carlo Erba SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmitalia Carlo Erba SRL, Carlo Erba SpA filed Critical Farmitalia Carlo Erba SRL
Publication of AU3351593A publication Critical patent/AU3351593A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0014—Androstane derivatives substituted in position 17 alfa, not substituted in position 17 beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0025—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

DIFLUOROMETHYLENANDROSTENONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION The present invention relates to new 6-difluoromethylen- androstenones, to a process for their preparation, to pharmaceutical compositions containing them, and to their use as therapeutic agents, in particular in the treatment of hormone-dependent diseases in mammals.
Basic and clinical data indicate that aromatized metabolites of androgens, i.e. the estrogens, are the hormones involved in the pathogenic cellular changes associated with the growth of some hormone-dependent cancers, such as breast, endometrial and ovarian carcinomas.
Estrogens are also involved in the pathogenesis of benign prostatic hyperplasia.
Endogenous estrogens are ultimately formed from either androstenedione or testosterone as immediate precursors.
The reaction of central importance is the aromatization of the steroidic ring A, which is performed by the enzyme aromatase. As aromatization is a unique reaction and the last in the series of steps in the biosynthesis of estrogens, it has been envisaged that an effective inhibition of the aromatase, resulting from compounds able to interact with the aromatizing steps, may have useful application for controlling the amount of circulating estrogens, estrogen- dependent processes in reproduction, and estrogen-dipendent tumours.
Known steroidal substances which have been reported to be endowed with an aromatase-inhibiting action are, for example, Δ1-testololactone (U.S. Pat. 2,744,120), 4-hydroxy- androst-4-ene-3, 17-dione and esters thereof (see, for example, U.S.Pat. 4,235,893), 10-(1,2-propadienyl)-estr-4-ene-3, 17- dione (U.S.Pat.4,289,762), 10-(2-propynyl)-estr-4-ene-3,17-dione (J. Amer.Chem.Soc., 103, 3221 (1981) and U.S.Pat.4,322,416), 19-thioan- drostene derivatives ( Europ. Pat . Appl. 100, 566), androsta-4,6-diene-3, 17-dione, androsta-1,4,6-triene-3,17-dione (G.B. Pat. Appl.2,100,601A), androsta-1,4-diene-3,17-dione (Cancer Res. (Suppl.) 42,
3327 (1982)), 6-alkenylen-androsta-1,4-diene-3,17-diones (U.S. Pat. 4,808,816 and U.S. Pat. 4,904,650) and 6-alkenyl- en-androsta-1,4-dien-17-ol-3-one derivatives (U.S. Pat.
4,873,233).
The present invention provides new compounds having the following general formula (I)
(I)
wherein
the symbol --- represents a double or single bond; R is hydrogen or C1-C4 alkyl; and
A is a C=O, CH OH or CH OR
1 group, in which R1 is
an acyl group.
Compounds falling within the scope of formula (I) above are all the possible isomers, stereoisomers and their mixtures, and the metabolites and the metabolic precursors or bio- precursors of the compound of formula (I). In the formulae of this specification the heavy solid lines indicate
that a substituent is in the β-configuration, i.e. above the plane of the ring, whereas a dotted line (,,,,,,) indicates that a substituent is in the α-configuration, and a wavy line indicates that a substituent may be either in the
α-configuration, i.e. below the plane of the ring, or in the β-configuration or in both, i.e. a mixture thereof.
In particular when in the compounds of formula (I) A is OH or OR the OH or OR substituent may be either in the α- or in the β-configuration or in both, i.e. a mixture thereof. Analogously, when the symbol ----- is a single bond, the R substituent may be either in the α- or β-configuration or in both, i.e. a mixture thereof.
The present invention includes all
the possible isomers, e.g. the single 1α, 17α; 1α, 17β;
1β,17α and 1β, 17β epimers, as well as all possible mixtures thereof, e.g. 1(α, β), 17α; 1(α, β), 17β; 1α, 17(α, β); 1 β , 17 (α , β ) and 1(α , β), 17(α, β)-isomers of the compounds of formula (I). Hence a compound of the invention herein specifically mentioned, without any indication of its stereochemistry, represents all the possible single isomers or mixtures thereof.
A C1-C4 alkyl group is preferably a methyl or ethyl group, more preferably a methyl group. The alkyl radical may be a branched or straight chain radical.
R1 as an acyl group may be residue of any physiologically tolerable acid. Preferred examples of said acids are
C1-C4alkanoic acids, in particular acetic, propionic and butyric acids.
As stated above, the present invention also includes within its scope pharmaceutically acceptable bio-precursors (otherwise known as pro-drugs) of the compounds of formula (I), i.e. compounds which have a different formula to formula (I) above but which nevertheless upon administration to a human being are converted directly or indirectly in vivo into a compound of formula (I).
Preferred compounds of the invention are the compounds of formula (I) wherein
A is a -C=O or -CH OH group;
R is hydrogen; and
the symbol represents a single or double bond.
Examples of specific compounds of the invention are the following compounds which, when appropriate, may be either α- or β-epimers or α, β-mixtures of said epimers:
6-difluoromethylenandrost-4-ene-3,17-dione;
6-difluoromethylenandrost-4-en-17α-ol-3-one;
6-difluoromethylenandrost-4-en-17β-ol-3-one;
6-difluoromethylenandrosta-1,4-diene-3,17-dione;
6-difluoromethylenandrosta-1,4-dien-17α(-ol-3-one; and
6-difluoromethylenandrosta-1,4-dien-17B-ol-3-one.
The compounds of the invention can be obtained by a process comprising:
a) dehydrofluorinating a compound of formula (II) I)
wherein
R is as defined above, thus obtaining a compound of formula (I) wherein the symbol --- is a single bond and
A is a CO group; or
b) dehydrogenating a compound of formula (III)
wherein
R is as defined above , thus obtaini ng a compound of formula ( I ) wherein the symbol --- is a double bond and
A is a CO group; or
c) reducing selectively a compound of formula (IV)
wherein
R and the symbol --- are as defined above, thus obtaining a compound of formula (I) wherein R and the symbol --- are as defined above and A is a H OH group; or
d) acylating a compound of formula (V)
wherein
R and the symbol --- are as defined above, thus obtaining a compound of formula (I) wherein R and the symbol --- are as defined above and A is a CH OR group in
which R1 is an acyl group; and, if desired, converting a compound of formula (I) into another compound of formula (I), and/or, if desired, separating a mixture of isomers of compounds of formula (I) into the single isomers.
The dehydrofluorination of a compound of formula (II) can be carried out by using basic dehydrohalogenation agents such as pyridine or a LiBr-Li2CO3-DMF mixture. Preferably the dehydrofluorination is carried out by chromatographing the raw steroid on neutral or basic alumina and using as eluant an inert solvent such as benzene, dichloromethane or ethyl acetate.
The dehydrogenation of a compound of formula (III) may be performed according to known methods, e.g. by treatment with DDQ, according to D. Walker and J.D. Hiebert: Chem. Rev. 67, 156 (1967), or by treatment with selenium dioxide, chloranil or benzeneseleninic acid. Preferably the reaction is performed by treatment with benzeneseleninic anhydride in an inert organic solvent, such as chlorobenzene or carbon tetrachloride, at a temperature ranging from about 60°C to about 120°C and reaction times varying from about 2 to about 48 hours.
The selective reduction of a compound of formula (IV) may be carried out by a well known method, for example as des cribed by C. Djerassi in Steroid Reactions (1963) or by J. Fried in Organic Reactions in Steroid Chemistry Vol. I (1972). Preferably the reduction is carried out with a complexed metal hydride, in particular with sodium borohydride in an inert organic solvent, in particular in methanol solution at temperatures ranging from about 0 to about
50°C.
The acylation of a compound of formula (V) can be performed by reaction with a reactive derivative of a suitable carboxylic acid, such as an anhydride or halide, in the presence of a basic agent, at temperatures ranging from about 0 to about 50°C. Preferably the acylation is carried out by reaction with the respective anhydride in the presence of an organic base, such as pyridine.
The separation of a mixture of isomers into the single isomers as well as the conversion of a compound of formula (I) into another compound of formula (I) may be carried out according to known methods. For example a 17β-hydroxy derivative of a compound of formula (I) may be converted into the respective 17α-hydroxy derivative by basic catalysis, e.g. with 0.1N sodium hydroxide in an aliphatic alcohol, e.g. ethanol.
Similarly, processes b), c) and d) can be regarded as optional conversions of a compound of formula (I) into an- other compound of formula (I). In fact, a compound of for mula (III) is a compound of formula (I) wherein the symbol --- is a single bond, A is CO and R is as herein defined.
A compound of formula (IV) is a compound of formula (I) wherein A is CO and the symbol --- and R are as herein
defined; and a compound of formula (V) is a compound of formula (I) wherein A is CH OH and the symbol --- and
R are as herein defined.
A compound of formula (II) can be obtained by oxidizing a compound of formula (VI)
wherein R is as defined above.
The oxidation of a compound of formula (VI) can be performed according to known methods, e.g. by treatment with the Jones reagent as described by Fieser and Fieser in Reagents for Organic Synthesis 1, 142 (Wiley 1967). Jones reagent is a solution of chromic acid and sulfuric acid in water. The oxidation may be carried out by titrating a stirred solution of the alcoholic compound in acetone at temperatures ranging from about -20°C to about 30°C with the Jones reagent. A compound of formula (VI) wherein R is as defined above may be obtained by saponification of a compound of formula (VII)
wherein R is as defined above and R1, being as herein defined, is preferably a lower alkanoyl group, in particular acetyl.
The saponification may be performed by a conventional method, e.g. by treatment with an alkali metal hydroxide in alcoholic solution, preferably with potassium hydroxide in methanol or ethanol at temperatures ranging from about 20°C to reflux temperature.
A compound of formula (VII), wherein R and R1 are as defined above, may be obtained from a compound of formula (VIII)
wherein R and R1 are as defined above by applying e.g. the method described in U.S. Pat. 3,504,002. Accordingly, the 6-ketosteroid of formula (VII) is treated with at least equimolar amounts of tributylphosphine and sodium chloro- difluoroacetate, at a temperature in the range of 150 - 200°C, using as solvent disubstituted hydrocarbon amide. It is viewed as involving the in situ production of tri- butylphosphinedifluoromethylene, which reacts with the 6-keto group. Alternatively, the method mentioned in U.S. Pat. 4,567,000 can be used. Accordingly, a solution of the protected 6-ketosteroid in an inert solvent such as THF, dioxane or diglyme is added to a cold solution of (di- ethylphosphinyl )difluoromethyllithium at about -60°C to about -80°C. This reagent may be prepared by treatment of diethyl difluoromethylphosphonate with 1.1 equivalent of lithium diisopropylamide in THF at -78ºC.
A compound of formula (VIII) wherein R and R1 are as defined above may be obtained by oxidation of a compound of formula (IX)
in which R and R1 are as defined above. This conversion may be performed according to a well known oxidation method in steroid chemistry, e.g. according to the method described above.
A compound of formula (IX) wherein R and R1 are as defined above may be obtained by cleavage of the 5β, 6β-epoxide ring in a compound of formula (X)
wherein R and R1 are as defined above.
The cleavage may be carried out, e.g., accordingly to
H.B. Henbest et al. (J. Chem. Soc. 1957, 4765) by reaction with the boron trifluoride-ether complex in an inert organic solvent such as benzene or ethyl ether at temperatures ranging from about 0 to 50°C. In the case of 5,6β- epoxide, the cleavage affords the diaxial 5α, 6β-fluoro- hydrin as desired.
A compound of formula (X), wherein R and R1 are as defined above, may be obtained from a compound of formula (XI)
(XI) wherein R and R1 are as defined above;
by dehydrobromination, e.g. according to J.F. Templeton et al. in J. Chem. Soc. Perkin Trans. I, 1361 (1987). Thus a solution of the 5α, 6β-bromohydrin in an inert organic solvent, such as dichloromethane or THF, is stirred with basic alumina at room temperature. Alternatively, the 5α, 6β-bromohydrin can be treated with a weak base such as sodium acetate in alcoholic solution, e.g. in methanol, at temperatures ranging from about 20°C to reflux temperature, e.g. as described in Belg. Pat. 625,669.
A compound of formula (XI), wherein R and R1 are as defined above, may be obtained from a compound of formula (XII)
(XII)
wherein R and R1 are as defined above;
by treatment with a N-bromoamide such as N-bromoacetamide or N-bromosuccinimide in the presence or not of perchloric acid in an aqueous solvent mixture such as aqueous dioxan or aqueous 1,2-dimethoxyethane at temperatures ranging from about 0°C to room temperature, e.g. as described in J. Chem. Soc. 1959, 4108.
The compounds of formula (XII) are known compounds or may be obtained by known methods from known compounds. When in the new compounds of the present invention and in the intermediate products thereof groups are present which need to be protected before submitting them to the here- above illustrated reactions, they may be protected before the reactions take place and then deprotected at the end of the reaction, according to well known methods in organic chemistry.
The compounds of the present invention are inhibitors of the biotransformation of androgens into estrogens, i.e., they are steroidal aromatase inhibitors. The aromatase inhibitory activity of these compounds was demonstrated by employing the in vitro test described by Thompson and Siiteri (E.A. Thompson and P.K. Siiteri, J. Biol. Chem. 249, 5364, 1974) which utilizes the human placental microsomal fraction as enzyme source. In this test the aromatization rate of androstenedione into estrone was evaluated by incubating (1β-3H)androstenedione (50 nM) in the presence of NADPH with the enzyme preparation and by measuring the amount of 3H2O formed during 20 min incubation at 37°C.
The compounds, incubated at various concentrations, showed a relevant aromatase inhibitory activity.
By virtue of their ability to inhibit aromatase and, consequently, to reduce estrogen levels, the compounds of the invention are useful in mammals, including humans, in the treatment and prevention of various estrogen-dependent diseases, i.e. breast, endometrial, ovarian and pancreatic cancers, gynecomastia, benign breast disease, endometriosis, polycystic ovarian disease and precocious puberty. Another application of the compounds of the invention is in the therapeutic and/or prophylactic treatment of prostatic hyperplasia, a disease of the estrogen-dependent stromal tissue.
The compounds of the invention can find also use for the treatment of male infertility associated with oligospermia and for female fertility control, by virtue of their ability to inhibit ovulation and egg nidation.
In view of their low toxicity the compounds of the invention can be used safely in medicine. For example, the approximate acute toxicity (LD50) of the compounds of the invention in the mouse, determined by single adminis tration of increasing doses and measured on the seventh day after the treatment was found to be negligible.
The compounds of the invention can be administered in a variety of dosage forms, e.g. orally, in the form of tablets, capsules, sugar or film coated tablets, liquid solutions or suspensions; rectally, in the form of suppositories; parenterally, e.g. intramuscularly, or by intravenous injection or infusion.
The dosage depends on the age, weight, conditions of the patient and admininistration route; for example, the dosage adopted for oral administration to adult humans may range from about 10 to about 150-200 mg pro dose, from 1 to 5 times daily.
The invention Includes pharmaceutical compositions comprising a compound of the invention in association with a pharmaceutically acceptable excipient (which can be a carrier or diluent).
The pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.
For example the solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. a starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs, sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Said pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating, or film-coating processes. The liquid dispersions for oral administration may be e.g. syrups, emulsions and suspensions.
The syrups may contain as carrier, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
The suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
The suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride. The solutions for intravenous injections or infusions may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.
The suppositories may contain together with the active compound a pharmaceutically acceptable carrier, e.g.
cocoa-butter, polyethylene glycol, a polyoxyethylene
sorbitan fatty acid ester surfactant or lecithin.
The present invention also provides a compound of formula (I) for use in a method of treatment of the human or animal body by therapy, especially for use as an aromatase
inhibitor.
The present invention additionally provides the use of a compound of formula (I) in the manufacture of a medicament for use as an aromatase inhibitor.
The present invention further provides a method of
inhibiting aromatase in mammals, including humans, which comprises applying thereto an effective amount of a compound of formula (I).
The present invention still further provides an aromatase inhibiting agent comprising a compound of formula (I).
The following examples further illustrate the invention:
Example 1 (I, A= C=O, R=H, --- single bond)
First Jones reagent is prepared by dissolving 2.672 g of chromic trioxide in 2.3 ml of cone. sulfuric acid and diluting with water to a volume of 10 ml. Then to a stirred solution of 6-difluoromethylene-5α(-fluoroandrostan-3,17- diol (358 mg, 1 mmol) in acetone (30 ml) is added portionwise under cooling 2 ml Jones reagent. After stirring for ½ h at 10-15°C and another½ h at 20-25°C, methanol ( 1 ml ) is added to destroy excess reagent. The resultant green solution is filtered to remove the chromium salts and then carefully diluted with water in order to precipitate raw 6-difluoromethylene-5α-fluoroandrostan-3,17-dione. The precipitate is filtered off, desiccated, dissolved in
benzene (10 ml) and adsorbed onto a basic alumina column (20 g). Finally elution with benzene-ether affords pure 6-difluoromethylene-androst-4-ene-3,17-dione (167 mg, 50% yield).
C20H24F2O2 calcd: C 71.83 H 7.23 F 11.36
found: C 71.71 H 7.11 F 11.42
IR cm-1: 1740 (17-CO), 1725 (C=CF2), 1670 (3-CO), 1620
MS (m/z): 334
Example 2 (I, A= C=O, R=H, --- double bond)
A solution of 6-difluoromethylenandrost-4-ene-3,17-dione (334 mg, 1 mmol) and benzene selenic anhydride (360 mmol) in chlorobenzene (30 mol) is heated for 4 h at 90-100°C. Then the solvent is removed in vacuum and the residue
chromatographed on silica gel with benzene-ether mixture as eluant thus giving pure 6-difluoromethylenandrosta-1,4- diene-3,17-dione (266 mg, 80% yield).
C20H22F2O2 calcd: C 72.27 H 6.67 F 11.43
found: C 72.15 H 6.55 F 11.35
IR cm-1: 1735 (17-CO), 1720 (C=CF2), 1650 (3-CO), 1610 (Δ4) MS (m/z): 332. Example 3 (I, A= CH-OH, R=H, --- single or double bond)
To a stirred solution of 6-difluoromethylenandrost-4-ene- 3,17-dione (334 mg, 1 mmol) in methanol (20 ml) is added sodium borohydride (57 mg, 1.5 mmol) over a period of 10 min at 0°C and stirring is continued for 1 h at 0°C. After addition of few drops of acetic acid, the mixture is concentrated under vacuum, diluted with water and then extracted with ethyl acetate. The combined organic phases are washed with saline solution, dried over sodium sulfate and then evaporated in vacuum. The residue is submitted to column chromatography on silica gel. Gradient elution with benzene-ether mixtures affords pure 6-difluoromethylen- androst-4-en-17β-ol-3-one (202 mg, 60 % yield).
C20H26F2O2 calcd: C 71.40 H 7.79 F 11.30
found: C 71.31 H 7.68 F 11.15
IR cm-1: 3410 (OH), 1720 (C=CF2), 1675 (3-CO), 1625 (Δ4) MS (m/z): 336.
According to the above described procedure and starting from the appropriate compound of formula (IV)
respectively one can prepare the following products as single isomers, as well as their 17α, 17β-mixtures:
6-difluoromethylenandrost-4-en-17α-ol-3-one;
6-difluoromethylenandrosta-1,4-dien-17α-ol-3-one; and 6-difluoromethylenandrosta-1,4-dien-17β-ol-3-one. Example 4
A solution of 3β,17β-diacetoxy-6-difluoromethylene-5α- fluoroandrostane (442 mg, 1 mmol) in methanol (15 ml) containing potassium hydroxide (336 mg, 6 mmol) is refluxed for 4 h. The reaction mixture Is concentrated under vacuum, diluted with water and extracted with ethyl acetate. The combined organic layers are washed with saline solution, dried over magnesium sulfate and evaporated under reduced pressure. The residue is crystallized from acetone-hexane giving pure 6-difluoromethylene-5α-fluoroandrostane-3,17- diol (323 mg, 90 % yield).
C20H29F3O2 calcd: C 67.02 H 8.15 F 15.90
found: C 67.10 H 8.05 F 15.81 MS (m/z): 358.
IR cm-1: 3350 (OH), 1720 (C=CF2)
Example 5
A solution of 3β,17β-diacetoxy-5α-fluoroandrostan-6-one (408 g, 1 mmol) and tributylphosphine (344 mg, 1.7 mmol) in N-methyl-2-pyrrolidone ( 2 ml ) is heated to 180°C. To this solution is added dropwise during 40 min a solution of sodium chlorodifluoroacetate (401 mg, 3.3 mmol) in N-methyl-2-pyrrolidone (6 ml). The reaction mixture is dissolved in benzene after cooling and the solution submitted to column chromatography. Gradient elution with benzene-ether mixture affords besides starting material the desired 3β,17β-diacetoxy-6-difluoromethylene-5α-fluoroandrostane (133 mg, 30 % yield).
C24H33F3O4 calcd: C 65.14 H 7.52 F 12.88
found: C 65.05 H 7.44 F 12.75
MS (m/z): 442.
IR cm-1: 1740 (-OCOCH3), 1725 (C=CF2).
Example 6
To a solution of 3β,17β-diacetoxy-5α-fluoroandrostan-6β- ol (408 mg, 1 mmol) in acetone (20 ml) is added portionwise Jones reagent (1 ml) under cooling at 10-15°C. The stirring is continued for ½ h at 10-15°C and another ½ h at 20-25°C. After addition of methanol (1 ml), the green mixture is filtered and the filtrate carefully diluted with water In order to precipitate the raw product. This is filtered off and chromatographed on silica gel using gradient elution with benzene-ether mixtures. Thus pure 3β,17β-diacetoxy-5α-fluoroandrostan-3-one is obtained (327 mg, 80 % yield).
C23H33FO5 calcd: C 67.62 H 8.14 F 4.65
found: C 67.45 H 8.05 F 4.57 MS (m/z): 408.
IR cm-1 : 1735 (acetate), 1705 (6-ketone).
Example 7
A solution of 3β,17β-diacetoxy-5, 6β-epoxyandrostane (389 mg, 1 mmol) in benzene (20 ml) is treated with boron trifluoride etherate (227 mg, 1.6 mmol) at 20-25°C for % h. The solution is washed with water, dried over potassium carbonate and the solvent evaporated under vacuum. The residue is chromatographed as usually to give pure 3β,17β- diacetoxy-5α-fluoro-androstan-6β-ol (308 mg, 75 % yield). C23H35FO5 calcd: C 67.29 H 8.59 F 4.63
found: C 67.15 H 8.46 F 4.55
MS (m/z): 408
IR cm-1: 3350 (hydroxy), 1735 (acetate)
Example 8
A solution of 5α-bromo-3β,17β-diacetoxyandrostan-6β-ol (471 mg, 1 mmol) in dichloromethane (25 ml) containing basic alumina (3 g) is stirred for 2 h at 20-25°C. The alumina is filtered off, the residue washed with dichloromethane and the combined filtrate evaporated under vacuum. The residue is crystallized from dichloromethane-acetone to afford pure 3β,17β-diacetoxy-5,6β-epoxyandrostane
(233 mg, 60 % yield).
C23H34O5 calcd: C 70.74 H 8.78
found: C 70.55 H 8.65
MS (m/z): 390
IR cm-1: 1735 (acetate). Example 9
A solution of 3β,17β-diacetoxyandrost-5-ene (379 mg, 1 mmol) in dioxan (5 ml) is treated with N-bromoacetamide (193 mg, 1.4 mmol), perchloric acid 70 % (0.1 ml) and water (1 ml) for ½ h at 20-25°C. The mixture is diluted with water and then extracted with benzene. The organic layer is separated, washed with water, dried over sodium sulfate and evaporated in vacuum. The residue is crystallized from chloroform-hexane to give pure 5α-bromo-3β,17β- diacetoxy-androstan-6β-ol (306 mg, 65 % yield).
C23H35BrO5 calcd: C 58.60 H 7.48 Br 16.95
found: C 58.30 H 7.35 Br 16.60
MS (m/z): 471
IR cm-1: 3350 (OH), 1735 (acetate).
Example 10
Tablets each weighing 0.150 g and containing 25 mg of the active substance, were manufactured as follows:
Composition (for 10,000 tablets):
6-difluoromethylenandrost-4-ene-3,17-dione 250 g
Lactose 800 g
Corn starch 415 g
Talc powder 30 g
Magnesium stearate 5 g The 6-difluoromethylenandrost-4-ene-3,17-dione, the lactose and half the corn starch were mixed; the mixture was then forced through a sieve of 0.5 mm mesh size. Corn starch (10 g) was suspended in warm water (90 ml) and the resulting paste was used to granulate the powder.
The granulate was dried, comminuted on a sieve of 1.4 mm mesh size, then the remaining quantity of starch, talc and magnesium stearate was added, carefully mixed and processed into tablets.
Example 11
Capsules, each dosed at 0.200 g and containing 20 mg of the active substance were prepared.
Composition for 500 capsules:
6-difluoromethylenandrost-4-en-17β-ol-3-one 10 g
Lactose 80 g
Corn starch 5 g
Magnesium stearate 5 g
This formulation was encapsulated in two-piece hard gelatin capsules and dosed at 0.200 g for each capsule.

Claims (10)

CLAIMS :
1. A compound having the following general formula (I)
wherein
the symbol --- represents a double or single bond;
R is hydrogen or C1-C4 alkyl; and
A is a C=O, OH or OR
1 group, in which
R1 is an acyl group.
2. A compound of formula (I), according to claim 1, wherein
A is a C O or OH group;
R is hydrogen; and
the symbol --- represents a single or double bond.
3. A compound selected from
6-difluoromethyleneandrost-4-ene-3,17-dione;
6-difluoromethylenandrost-4-en-17α-ol-3-one;
6-difluoromethylenandrost-4-en-17β-ol-3-one;
6-difluoromethylenandrosta-1,4-diene-3,17-dione;
6-difluoromethylenandrosta-1,4-dien-17α-ol-3-one; and 6-difluoromethylenandrosta-1,4-dien-17β-ol-3-one; which, when appropriate, may be either α - or β-epimer or α,β-mixture of said epimers.
4. A process for the preparation of a compound of formula (I), according to claim 1, the process comprising a) dehydrofluorinating a compound of formula (II)
wherein
R is as defined in claim 1, thus obtaining a compound of formula (I) wherein the symbol --- is a single bond and A is a CO group; or
b) dehydrogenating a compound of formula (III)
wherein
R is as defined in claim 1, thus obtaining a compound of formula (I) wherein the symbol --- is a double bond and A is a CO group; or
c) reducing selectively a compound of formula (IV)
(IV)
wherein
R and the symbol --- are as defined in claim 1, thus obtaining a compound of formula (I) wherein the symbols --- and R are as defined in claim 1 and A is a
OH group; or
d) acylating a compound of formula (V)
(V)
wherein
R and the symbol --- are as defined in claim 1, thus obtaining a compound of formula (I) wherein R and the symbol --- are as defined in claim 1 and A is a OR1 group in which R1 is an acyl group; and, if desired, converting a compound of formula (I) into another compound of formula (I), and/or, if desired, separating a mixture of isomers of compounds of formula (I) into the single isomers.
5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and/or diluent and, as an active principle, a compound of formula (I) as claimed in claim 1.
6. A compound of formula (I), as defined in claim 1, for use in a method of treatment of the human or animal body by therapy.
7. A compound of formula (I), as defined in claim 1, for use as an aromatase inhibitor.
8. Use of a compound of formula (I), as defined in
claim 1, in the manufacture of a medicament for use as an aromatase inhibitor.
9. A method of inhibiting aromatase in mammals which
comprises applying thereto an effective amount of a compound of formula (I) according to claim 1.
10. An aromatase inhibiting agent comprising a compound of formula (I) according to claim 1.
AU33515/93A 1992-01-21 1993-01-18 Difluoromethylenandrostenone derivatives and process for their preparation Abandoned AU3351593A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9201224 1992-01-21
GB929201224A GB9201224D0 (en) 1992-01-21 1992-01-21 Difluoromethylenandrostenone derivatives and process for their preparation

Publications (1)

Publication Number Publication Date
AU3351593A true AU3351593A (en) 1993-08-03

Family

ID=10708955

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33515/93A Abandoned AU3351593A (en) 1992-01-21 1993-01-18 Difluoromethylenandrostenone derivatives and process for their preparation

Country Status (10)

Country Link
JP (1) JPH06507181A (en)
AU (1) AU3351593A (en)
CA (1) CA2106457A1 (en)
FI (1) FI934093A (en)
GB (1) GB9201224D0 (en)
HU (1) HUT64968A (en)
IL (1) IL104204A0 (en)
MX (1) MX9300244A (en)
WO (1) WO1993014105A1 (en)
ZA (1) ZA9335B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9313420D0 (en) * 1993-06-29 1993-08-11 Erba Carlo Spa Fluorinated 6-methylenandrosta-1,4-dien-3-one-derivatives and process for their preparations
DE19633349A1 (en) * 1996-08-19 1998-02-26 Sigma Tau Ind Farmaceuti New 6-hydroxy and 6-oxo-androstane derivatives that act on the cardiovascular system and pharmaceutical compositions containing them

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8517360D0 (en) * 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
GB8622330D0 (en) * 1986-09-17 1986-10-22 Erba Farmitalia 4-substituted 6-alkylidenandrostene-3,17-dione derivatives
GB8721383D0 (en) * 1987-09-11 1987-10-21 Erba Farmitalia Preparation of methylene derivatives
GB8721384D0 (en) * 1987-09-11 1987-10-21 Erba Farmitalia 17-substituted andro-sta-1 4-dien-3-one derivatives
GB8801697D0 (en) * 1988-01-26 1988-02-24 Erba Farmitalia Improvements in synthesis of 6-methylene derivatives of androsta-1 4-diene-3 17-dione

Also Published As

Publication number Publication date
FI934093A0 (en) 1993-09-17
HU9302649D0 (en) 1993-12-28
ZA9335B (en) 1993-08-05
JPH06507181A (en) 1994-08-11
GB9201224D0 (en) 1992-03-11
IL104204A0 (en) 1993-05-13
HUT64968A (en) 1994-03-28
CA2106457A1 (en) 1993-07-22
FI934093A (en) 1993-09-17
WO1993014105A1 (en) 1993-07-22
MX9300244A (en) 1993-07-01

Similar Documents

Publication Publication Date Title
US4898694A (en) 17-Hydroxy-steroids
NL193616C (en) Substituted androsta-1,4-diene-3,17-dione, as well as pharmaceutical preparations containing such compounds.
JPH0121158B2 (en)
JP2643943B2 (en) Novel 6- or 7-methyleneandrosta-1,4-diene-3,17-dione derivative and method for producing the same
JP2677626B2 (en) 17-Substituted Androsta-1,4-dien-3-one Derivatives
US4840943A (en) Androst-4-ene-3,17-diones and process for their preparation
EP0210665B1 (en) Steroids useful as anti-cancer, anti-obesity, anti-hyperglycemic, anti-autoimmune and anti-hyper-cholesterolemic agents
EP0227472B1 (en) 10 beta-alkynylestrene derivatives and process for their preparation
AU666433B2 (en) Fluorinated 4-aminoandrostadienone derivatives and process for their preparation
AU3351593A (en) Difluoromethylenandrostenone derivatives and process for their preparation
EP0608404B1 (en) ANDROST-4-ENO[4,5-b]PYRROLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION
WO1995001366A1 (en) Fluorinated 6-methylenandrosta-1,4-dien-3-one derivatives and process for their preparation
GB2191777A (en) Methylene derivatives of androst-4-ene-3,17-diones and process for their preparation
WO1994010190A1 (en) 6,7α-DIFLUOROMETHYLENANDROSTA-1,4-DIEN-3-ONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION
GB2284605A (en) 6-or 7-substituted 4-aminoandrostadienone derivatives
GB2195639A (en) Polyconjugated androstenediones and process for their preparation
GB2185258A (en) 10 beta -Halo-alkynyl estrene derivatives and process for their preparation